NASDAQ: SBFM 👥 Enters Into A Collaboration Agreement For Its K1.1 Anticancer mRNA Project! 🔬
Detroit, Michigan --News Direct-- Sunshine Biopharma Inc.
Sunshine Biopharma (NASDAQ: SBFM) has entered into a collaboration agreement with one of North America's leading lipid nanoparticle ("LNP") formulation companies to advance the development of Sunshine Biopharma's mRNA-based anticancer macromolecule, K1.1! Learn more about this collaboration and its significance in this video! Sunshine Biopharma focuses on the research, development & commercialization of life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. Visit Sunshine Biopharma: https://sunshinebiopharma.com/ https://investors.sunshinebiopharma.com/
Contact Details
Christine Petraglia - TraDigital IR
+1 917-633-8980
investors@sunshinebiopharma.com
Company Website
https://sunshinebiopharma.com/
View original content to download multimedia: https://newsdirect.com/news/nasdaq-sbfm-enters-into-a-collaboration-agreement-for-its-k1-1-anticancer-mrna-project-126871532
This news release was distributed by News Direct Corp. (“News Direct”). News Direct is an industry-leading content and news distribution platform. This news release and all materials included within this news release, including, without limitation, all images, trademarks and logos, are protected by copyrights, trademarks, service marks, patents or other proprietary rights and laws. If you copy, broadcast, download, store (in any medium), transmit, show or play any multimedia content from this release in public, you must properly attribute said content to the company or organization from which the news release originated unless otherwise sourced. News Direct makes no warranties with respect to the accuracy or completeness of the information contained in this news release. News Direct hereby disclaims all warranties, whether express, implied, statutory or otherwise, in connection with this news release and the content within this news release.
